Skip to main content
. 2022 Apr 26;17(4):e0261234. doi: 10.1371/journal.pone.0261234

Table 1. Baseline characteristics of patients with hypoxemic respiratory failure.

All patients (n = 483) Patients with pneumonia (n = 263) Patients with non-pneumonia conditions (n = 220) p value
Median Age, (Years) 64 (55–74) 65 (55–74) 63 (56–73) 0.689
Male 345 (71.4%) 190 (72.2%) 155 (70.5%) 0.687
Median BMI (kg/m2) 22.9 (20.0–26.7) 22.8 (19.6–26.0) 22.9 (21.2–27.0) 0.074
Median APACHE II 19 (13–25) 19 (13–25) 20 (13–25) 0.633
Vasopressor use 94 (19.5%) 43 (16.4%) 51 (23.2%) 0.065
Smoking status
Smoker 86 (17.8%) 40 (15.2%) 46 (20.9%) 0.271
Ex-smoker 335 (69.4%) 188 (71.5%) 147 (66.8%)
Non-smoker 62 (12.8%) 35 (13.3%) 27 (12.3%)
Admission source
Emergency Department 207 (42.9%) 83 (37.7%) 124 (47.2%) <0.001*
General Ward 233 (48.2%) 102 (46.4%) 131 (49.8%)
Operating Theatre 43 (8.9%) 35 (15.9%) 8 (3.0%)
Comorbidities
Hypertension 282 (58.4%) 149 (56.65%) 133 (60.5%) 0.406
Diabetes 181 (37.5%) 100 (38.0%) 81 (36.8%) 0.850
Immunosuppression 133 (27.5%) 67 (25.5%) 66 (30.0%) 0.306
Chronic kidney disease 104 (21.5%) 59 (22.4%) 45 (20.5%) 0.657
Ischemic Heart Disease 103 (21.3%) 40 (15.2%) 63 (28.6%) 0.001*
COPD 34 (7.0%) 14 (5.3%) 20 (9.1%) 0.112
Stroke 32 (6.6%) 17 (6.5%) 15 (6.8%) 1.000
Asthma 28 (5.8%) 12 (4.6%) 16 (7.3%) 0.242
Liver cirrhosis 15 (3.1%) 7 (2.7%) 8 (3.6%) 0.604
Bronchiectasis 11 (2.3%) 8 (3.0%) 3 (1.4%) 0.359
Interstitial lung disease 9 (1.9%) 4 (1.5%) 5 (2.3%) 0.738
Outcomes
Median duration of HFNC use (Hrs) 23 (9–49) 23 (10–53) 21 (9–46) 0.614
Median ICU length of stay (days) 6 (3–10) 6 (3–11) 6 (3–10) 0.503
Median hospital length of stay (days) 18 (10–35) 15 (9–29) 21 (11–41) 0.023*
ICU mortality 71 (14.7%) 47 (17.9%) 24 (10.9%) 0.039*
Hospital mortality 120 (24.8%) 78 (29.7%) 42 (19.1%) 0.008*

* represents those parameters that are statistically significant.

** BMI = Body mass index, APACHE II = Acute Physiology and Chronic Health Evaluation II, ED = Emergency Department, COPD = Chronic obstructive pulmonary disease.